*NeuroNexus, Facilitating CDRH's Participation

NeuroNexus is a collaboratory of review groups within the Center for Devices and Radiological Health (CDRH), Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER) who review medical products used in the treatment, diagnosis, or management of neurological and psychiatric diseases and conditions. FDA is intending to announce this new cross-Center initiative in October 2027.The NeuroNexus collaboratory will formalize a program to connect the 3 FDA centers with the following main objectives:Expedite the development and review of novel therapies and diagnostics intended to treat, diagnose, or manage neurological and psychiatric disorders through shared knowledge, review efficiency, and cross-center communication.Engage with other government, academic, clinical professional, patients, and industry partners to obtain up-to-date knowledge and activities on identified project areas.Support congressionally mandated neuroscience programs, such as the Act for ALS, Neurology Drug Program, National Alzheimer's Prevention Act, etc.Share and track information on neuroscience related activities within each center

Estimated value

>= $1.5M and < $3M

Est. solicitation date

Jul 1, 2026

Anticipated award

Jan 1, 2027